BIOGEN INC. Repayments of Long-Term Debt
BIOGEN INC. (BIIB) reported Repayments of Long-Term Debt of $1.75 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-02-06
- BIOGEN INC. repayments of long-term debt for the quarter ending 2025-12-31 was $0.00.
- BIOGEN INC. repayments of long-term debt for the quarter ending 2025-09-30 was $0.00.
- BIOGEN INC. repayments of long-term debt for the quarter ending 2025-06-30 was $1.75B, a 600.00% increase year-over-year.
- BIOGEN INC. repayments of long-term debt for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. repayments of long-term debt for fiscal 2025 was $1.75B, a 169.23% increase from fiscal 2024.
- BIOGEN INC. repayments of long-term debt for fiscal 2024 was $650.00M, a 19.74% decline from fiscal 2023.
- BIOGEN INC. repayments of long-term debt for fiscal 2023 was $809.90M.
- BIOGEN INC. repayments of long-term debt for fiscal 2009 was $0.00.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 6 month as first filed | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 9 month as first filed | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $1.75B derived: sum of 3 quarters · filed 2026-02-06 | $1.75B 10-K · filed 2026-02-06 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.75B derived: sum of 2 quarters · filed 2025-10-30 | $1.75B 10-Q · filed 2025-10-30 | $1.75B derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2025-06-30 | $1.75B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.75B 10-Q · filed 2025-07-31 | $1.75B derived: sum of 3 quarters · filed 2026-02-06 | $1.75B derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-06 | $250.00M derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $250.00M derived: sum of 3 quarters · filed 2026-02-06 | $650.00M 10-K · filed 2026-02-06 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $250.00M derived: sum of 2 quarters · filed 2025-10-30 | $650.00M 10-Q · filed 2025-10-30 | $1.30B derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2024-06-30 | $250.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $650.00M 10-Q · filed 2025-07-31 | $1.30B derived: sum of 3 quarters · filed 2026-02-06 | $1.46B derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2024-03-31 | $400.00M 10-Q · filed 2025-05-01 | $1.05B derived: sum of 2 quarters · filed 2026-02-06 | $1.21B derived: sum of 3 quarters · filed 2026-02-06 | $1.21B derived: sum of 4 quarters · filed 2026-02-06 | ||
| 2023-12-31 | $650.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $809.90M derived: sum of 2 quarters · filed 2026-02-06 | $809.90M derived: sum of 3 quarters · filed 2026-02-06 | $809.90M 10-K · filed 2026-02-06 | ||
| 2023-09-30 | $159.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $159.90M derived: sum of 2 quarters · filed 2024-10-30 | $159.90M 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-04-24 | |||||
| 2022-09-30 | $1.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.00B derived: sum of 2 quarters · filed 2023-11-08 | $1.00B 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $0.00 10-Q · filed 2022-07-20 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $700.00K derived: sum of 2 quarters · filed 2022-10-25 | $170.00M 10-Q · filed 2022-10-25 | $0.00 10-Q · filed 2021-10-20 | ||
| 2021-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $170.00M 10-Q · filed 2022-07-20 | $0.00 10-Q · filed 2021-07-22 | |||
| 2021-03-31 | $169.30M 10-Q · filed 2022-05-03 | |||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $1.50B 10-Q · filed 2021-10-20 | ||||
| 2020-06-30 | $1.50B 10-Q · filed 2021-07-22 | |||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $0.00 10-Q · filed 2020-10-21 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2020-07-22 | |||||
| 2018-09-30 | $3.20M 10-Q · filed 2019-10-22 | |||||
| 2009-12-31 | $0.00 10-K · filed 2010-02-09 | |||||
| 2008-12-31 | $0.00 10-K · filed 2010-02-09 | |||||
| 2007-12-31 | $6.56M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |